Leadman(SZ:300289) Ge Long Hui A P P·2025-11-13 12:29Core Viewpoint - Company plans to acquire 70% stake in Xiansheng Xiangrui for a total consideration of 173.3 million yuan, aiming to enhance its position in the biopharmaceutical industry, particularly in tuberculosis diagnostics [1][2] Group 1: Acquisition Details - The acquisition involves cash payment to Shanghai Baijiahui Investment Management Co., Nanjing Baijiarui Enterprise Management Consulting Partnership, and Hainan Xiansheng Baijiahui Technology Development Co. for their combined 70% stake in Xiansheng Xiangrui [1] - Xiansheng Xiangrui specializes in the R&D, production, and sales of biological products, including in vitro diagnostic reagents and vaccines, with a focus on tuberculosis screening and diagnosis [1] Group 2: Market Position and Product Offering - Xiansheng Xiangrui's core product, TB-PPD, is the only product of its kind in China and is included in the Pharmacopoeia of the People's Republic of China, the National Essential Medicines List, and is classified as a Class A medical insurance drug [1] - The company aims to create a comprehensive product matrix for tuberculosis, covering initial screening, diagnosis, confirmation, drug resistance testing, and treatment [1] Group 3: Strategic Implications - By acquiring control of Xiansheng Xiangrui, the company can quickly enter the high-barrier biopharmaceutical industry, significantly reducing the time and risk associated with developing new products and establishing market channels [2] - This strategic move allows the company to achieve business transformation and develop a dual main business model of "biopharmaceuticals + in vitro diagnostics," driving growth through both independent R&D and external collaboration [2]